For the second week in a row, deal activity hit highs not seen thus far in 2022, with at least 13 deals over $1 billion reported, along with four new SPAC mergers. Still, SPACs and IPOs remained suppressed, with neither registering an entrant in the last week.
Among those 13 $1 billion deals were three mega-deals over $5 billion. That includes two big deals announced Monday: Pfizer, with counsel from Wachtell, Lipton, Rosen & Katz, agreeing to a $5.4 billion deal for Global Blood Therapeutics, advised by Cravath, Swaine & Moore and Goodwin Procter. Meanwhile, in an $8.4 billion deal, private equity firm Vista Equity Partners, advised by Kirkland & Ellis, said it will acquire tax software provider Avalara Inc., which has turned to Simpson Thacher & Bartlett and Perkins Coie for legal advice.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]